Mei Wang

Associate Professor

Duke-NUS Medical School

Singapore

Research Interests

Explore related searches

Professors in Cancer Biology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mei Wang is an Associate Professor at Duke-NUS Medical School in Singapore. Her research focuses on oncogenic mutations, cancer cell stemness, and the regulatory mechanisms involved in cancer progression. Recent publications highlight her contributions to understanding the roles of RAB4A, GNA13, and the RAS/RAF/MEK/ERK signaling pathways in cancer therapies.

Articles (8)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (4)

Edward Tate

Professor of Chemical Biology

Imperial College London

UNITED KINGDOM

View details

Suhail Ahmed Kabeer Rasheed

Assistant Professor

Duke-NUS Medical School

SINGAPORE

View details

Patrick Casey

Senior Vice Dean of Research

Duke-NUS Medical School

SINGAPORE

View details

Ufuk Degirmenci

Head of Spatial Biology/Senior Scientist

Genome Institute of Singapore

SINGAPORE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mei Wang

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold

Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets

RAB4A is a master regulator of cancer cell stemness upstream of NUMB–NOTCH signaling

GNA13 suppresses proliferation of ER+ breast cancer cells via ERα dependent upregulation of the MYC oncogene.

Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair

The emerging roles of Gα12/13 proteins on the hallmarks of cancer in solid tumors

Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Collaborators (4)

Edward Tate

Suhail Ahmed Kabeer Rasheed

Patrick Casey

Ufuk Degirmenci

Make your next move.